利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

209 条记录 (耗时 0.033 秒)

    EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES
    41.
    发明申请
    EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES 有权
    异位传染性病毒性肝炎病毒感染和疾病诊断

    公开(公告)号：US20140134606A1

    公开(公告)日：2014-05-15

    申请号：US14159612

    申请日：2014-01-21

    申请人： MOREHOUSE SCHOOL OF MEDICINE

    发明人： Gale W. NEWMAN ,  Sam Anyanwu

    IPC分类号： C12Q1/70

    CPC分类号： G01N33/56988 ,  C12Q1/70 ,  C12Q1/703 ,  C12Q1/706 ,  C12Q1/707 ,  G01N1/40 ,  G01N33/493 ,  G01N33/56983 ,  G01N33/576 ,  G01N33/6893 ,  G01N2333/02 ,  G01N2333/10 ,  G01N2333/161 ,  G01N2333/162 ,  G01N2333/163 ,  G01N2333/186 ,  G01N2800/347 ,  G01N2800/52 ,  G01N2800/56

    摘要： A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.

    摘要翻译： 公开了一种用于诊断受试者中基于肝炎病毒相关生物标志物的肝炎病毒感染或肝炎病症的方法，所述肝炎病毒相关生物标志物存在于来自受试者的体液样品中的外来体上。 还公开了一种用于监测受试者中肝炎病毒感染或肝炎疾病状况的过程的方法以及基于存在于外来体上的肝炎病毒相关生物标志物来监测具有抗肝炎病毒剂的受试者治疗有效性的方法 来自受试者的体液样本，以及用于诊断受试者中基于肝炎病毒相关生物标志物的肝炎病毒感染和/或肝炎疾病状况的试剂盒，其来自受试者的体液样品中的外来体。

    Methods for the Phenotypic Detection of HCV Inhibitor Resistant Subpopulations
    42.
    发明申请
    Methods for the Phenotypic Detection of HCV Inhibitor Resistant Subpopulations 审中-公开
    HCV抑制剂抗性亚群体表型检测方法

    公开(公告)号：US20130302782A1

    公开(公告)日：2013-11-14

    申请号：US13692979

    申请日：2012-12-03

    申请人： Laboratory Corporation of America Holdings

    发明人： Jacqueline Denise Reeves ,  Christos John Petropoulos ,  Wei Huang

    IPC分类号： C12Q1/70

    CPC分类号： C12Q1/707 ,  G01N33/5023 ,  G01N33/576 ,  G01N33/5767

    摘要： Methods and compositions for the efficient and accurate determination of susceptibility of a hepatitis C virus (HCV) population to an HCV inhibitor are provided. In certain aspects, the methods involve introducing into a cell a patient derived segment, wherein the cell or the patient derived segment comprises an indicator nucleic acid that produces a detectable signal that is dependent on the HCV; measuring the expression of the indicator gene in the presence of varying concentrations of the HCV inhibitor; determining a standard curve of susceptibility; comparing the IC95 fold change, slope, or maximum inhibition percentage of the HCV population to that of a control HCV population, and determining that the HCV population comprises HCV with a reduced susceptibility to the inhibitor when the IC95 fold change value is increased or the slope and/or maximum inhibition percentage is lower for the HCV population as compared to the control population.

    摘要翻译： 提供了有效和准确地确定丙型肝炎病毒（HCV）群体对HCV抑制剂敏感性的方法和组合物。 在某些方面，所述方法包括向病人导入患者衍生的区段，其中所述细胞或所述患者衍生区段包含产生依赖于HCV的可检测信号的指示核酸; 在不同浓度的HCV抑制剂存在下测量指示基因的表达; 确定敏感性的标准曲线; 将HCV群体的IC95倍数，斜率或最大抑制百分比与对照HCV群体的IC95倍数，斜率或最大抑制百分比进行比较，并且当IC95倍数变化值增加时，确定HCV群体包含对抑制剂易感性降低的HCV， 和/或与对照群体相比，HCV群体的最大抑制百分比较低。

    Methods for detection of biological substances
    43.
    发明授权
    Methods for detection of biological substances 有权
    生物物质检测方法

    公开(公告)号：US08506934B2

    公开(公告)日：2013-08-13

    申请号：US12649320

    申请日：2009-12-29

    申请人： Robert I. Henkin

    发明人： Robert I. Henkin

    IPC分类号： A61K49/00 ,  G01N33/53 ,  G01N33/566 ,  A61P11/02

    CPC分类号： A61K31/522 ,  A61K9/0043 ,  A61K31/4709 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/118 ,  G01N33/566 ,  G01N33/57449 ,  G01N33/576 ,  G01N33/6893 ,  G01N2333/525 ,  G01N2333/70575 ,  G01N2800/042 ,  G01N2800/14 ,  G01N2800/52 ,  Y02A50/463 ,  Y02A50/54

    摘要： The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

    摘要翻译： 本发明涉及一种检测鼻分泌物中的生物物质的方法，并且在检测到生物物质与生物物质与呼吸系统疾病无关之后诊断疾病。 本发明还提供了在检测生物物质和/或诊断疾病之后的疾病的治疗。 在一些实施方案中，疾病是癌症，肝炎，气味丧失，味觉丧失，糖尿病和麻风病。 本发明还提供了用于诊断疾病的试剂盒。 本发明包括分析来自鼻子的样品用于检测生物物质的方法。 特别地，收集鼻分泌物或鼻粘液并分析生物物质。 该分析结果适用于诊断，预后和治疗干预适合性的测定。

    PIRFENIDONE TREATMENT FOR PATIENTS WITH ATYPICAL LIVER FUNCTION
    44.
    发明申请
    PIRFENIDONE TREATMENT FOR PATIENTS WITH ATYPICAL LIVER FUNCTION 有权
    皮炎酮治疗患有肝脏功能的患者

    公开(公告)号：US20120077850A1

    公开(公告)日：2012-03-29

    申请号：US13312746

    申请日：2011-12-06

    申请人： Williamson Z. Bradford ,  Javier Szwarcberg

    发明人： Williamson Z. Bradford ,  Javier Szwarcberg

    IPC分类号： A61K31/4418 ,  A61P35/00

    CPC分类号： A61K31/4412 ,  A61K31/4418 ,  G01N33/576 ,  G01N33/6893 ,  G01N2800/52 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/475

    摘要： Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.

    摘要翻译： 提供了用于向依托吡非尼酮给药反应呈现出肝功能异常生物标志物的患者施用吡非尼酮的方法。 所述方法包括以低于全部目标剂量的剂量给予患者吡非尼酮一段时间，然后以完全目标剂量施用于患者吡非尼酮。 所述方法还包括以完全目标剂量施用吡非尼酮，而不减少并施用永久减少剂量的吡非尼酮。

    Immunodiagnostic assays using reducing agents
    46.
    发明授权
    Immunodiagnostic assays using reducing agents 有权
    使用还原剂进行免疫诊断测定

    公开(公告)号：US07935490B2

    公开(公告)日：2011-05-03

    申请号：US11497259

    申请日：2006-08-02

    申请人： Geert Maertens ,  Joost Louwagie ,  Alfons Bosman ,  Erwin Sablon ,  Maan Zrein

    发明人： Geert Maertens ,  Joost Louwagie ,  Alfons Bosman ,  Erwin Sablon ,  Maan Zrein

    IPC分类号： C12Q1/70 ,  G01N33/543 ,  G01N33/53

    CPC分类号： C07K14/005 ,  C12N2770/24222 ,  C12Q1/707 ,  G01N33/54306 ,  G01N33/54393 ,  G01N33/576 ,  G01N33/5767

    摘要： The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent. The present invention also relates to a method for purifying a cysteine containing recombinantly expressed protein comprising at least 2, preferably 3 or 4 and even more preferably all of the following steps: (a) sulphonation of a lysate from recombinant host cells or lysis of recombinant host cells in the presence of guanidinium chloride followed by a subsequent sulphonation of the cell lysate, (b) treatment with a zwitterionic detergent, preferably after removal of the cell debris, (c) purification of the sulphonated version of the recombinant protein or purification of the sulphonated version of the recombinant protein with subsequent removal of the zwitterionic detergent, with said purification being preferably chromatography, more preferably a Ni-IMAC chromatography with said recombinant protein being a His-tagged recombinant protein, (d) desulphonation of the sulphonated version of the recombinant protein, preferably with a molar excess of DTT, (e) storage in the presence of a molar excess of DTT. The present invention also relates to novel HCV NS3 sequences as depicted in FIGS. 1-8.

    摘要翻译： 本发明涉及一种在还原剂存在下在所述固相上含有抗原的固相免疫测定法。 本发明还涉及一种纯化包含重组表达蛋白质的半胱氨酸的方法，其包含至少2个，优选3个或4个，甚至更优选全部以下步骤：（a）来自重组宿主细胞的裂解物的磺化或重组体的裂解 在氯化胍的存在下接受宿主细胞，随后细胞裂解物的磺化，（b）用两性离子洗涤剂处理，优选在去除细胞碎片后，（c）纯化重组蛋白的磺化版本或纯化 所述重组蛋白的磺化版本随后除去两性离子洗涤剂，所述纯化优选为色谱法，更优选为所述重组蛋白为His标记的重组蛋白的Ni-IMAC色谱，（d）磺化版本的 重组蛋白质，优选摩尔过量的DTT，（e）在mo存在下储存 少量DTT。 本发明还涉及如图1和2所示的新型HCV NS3序列。 1-8。